Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 5.
doi: 10.14309/ajg.0000000000003574. Online ahead of print.

Different Survival Outcomes of Small Bowel Adenocarcinomas and T-Cell Lymphomas Associated With Celiac Disease

Giovanni Santacroce  1   2 , Alessandro Vanoli  3   4 , Nicola Aronico  2 , Paola Ilaria Bianchi  2 , Marco Vincenzo Lenti  1   2 , Carolina Ciacci  5 , Fabiana Zingone  6 , Umberto Volta  7 , Antonio Calabrò  8 , Luca Elli  9 , Rachele Ciccocioppo  10 , Gino Roberto Corazza  1 , Marco Lucioni  4 , Marco Paulli  3   4 , Antonio Di Sabatino  1   2 ; Small Bowel Cancer Consortium
Collaborators, Affiliations

Different Survival Outcomes of Small Bowel Adenocarcinomas and T-Cell Lymphomas Associated With Celiac Disease

Giovanni Santacroce et al. Am J Gastroenterol. .

Abstract

Introduction: Small bowel adenocarcinoma (SBA) and T-cell lymphoma (TCL) are rare but aggressive malignancies associated with celiac disease (CD).

Methods: We retrospectively compared 43 CD-associated SBA and 43 CD-associated TCL across international referral centers.

Results: CD-associated SBA showed a significantly ( P < 0.01) better survival than CD-associated TCL. TCL more frequently presented with multifocal involvement and advanced stage, whereas SBA predominantly involved the jejunum. Refractoriness to a gluten-free diet was identified in 70% of TCL but only in one SBA.

Discussion: Our findings demonstrated a worse prognosis of CD-associated TCL in comparison with CD-associated SBA.

Keywords: enteropathy-associated T-cell lymphoma; gluten-free diet; immune-mediated disorders; malignancy-related survival; refractory celiac disease.

PubMed Disclaimer

References

    1. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009;373(9673):1480–93.
    1. Malamut G, Soderquist CR, Bhagat G, et al. Advances in nonresponsive and refractory celiac disease. Gastroenterology 2024;167(1):132–47.
    1. Lucioni M, Fraticelli S, Santacroce G, et al. Clinical and histopathological features of an Italian monocentric series of primary small bowel T-Cell lymphomas. Cancers (Basel) 2023;15(10):2743.
    1. Arpa G, Vanoli A, Antoci F, et al. A clinicopathologic comparison between early-onset and late-onset small bowel adenocarcinoma: A multicenter international study. Am J Gastroenterol 2024;119(3):576–9.
    1. Vanoli A, Di Sabatino A, Martino M, et al. Small bowel carcinomas in celiac or Crohn's disease: Distinctive histophenotypic, molecular and histogenetic patterns. Mod Pathol 2017;30(10):1453–66.

LinkOut - more resources